Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLD + Cyclophosphamide + Vincristine in Pediatric Solid Tumors
NCT04213612Phase 1Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Dec 2019
- Primary completion
- Aug 2020
- Modality
- DNA Intercalators/Alkylators
01
Overview
Phase 1, open-label, single-arm trial of doxorubicin in solid tumor, sponsored by Sun Yat-sen University. Primary endpoint: Maximum tolerated dose. Status: unknown.
02
Drugs
doxorubicin
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04213612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04213612.